Ohio Medication Assisted Treatment: What to Know

If you coordinate care for Ohioans living with opioid use disorder and a co-occurring mental health condition, the ground under your work has shifted in three directions at once: coverage, monitoring, and geography. Pharmacology matters, but it is no longer the hard part of the job in the Buckeye State.

On the coverage side, Ohio moved to remove the September 30, 2025 sunset on its Medicaid MAT benefit through State Plan Amendment OH-25-0021, aiming to make MAT a permanent benefit rather than a time-limited enhancement ⁶. That change matters for your patients because it stabilizes a funding stream many of them depend on to stay in treatment past the first difficult months. It also sits inside a federal baseline that required states to cover FDA-approved MAT drugs and biologicals for a five-year period beginning October 1, 2020 ⁸.

On the monitoring side, the Ohio Board of Pharmacy rolled out updated OARRS reporting standards effective July 1, 2025, tightening the data expectations for controlled-substance oversight ¹. In 2024, OARRS also began collecting information on non-fatal overdoses treated in Ohio emergency departments, giving prescribers a new clinical signal that lives inside the system you probably already check every shift ³.

On the geography side, access is still uneven. Peer-reviewed modeling found that over one-third of Ohio’s OUD treatment need was not covered by the existing OTP network, with coverage dropping as county rurality increased ¹². That is the Ohio you are actually practicing in — and where dual-diagnosis integration has the most to offer.

Coverage decisions drive retention decisions. In Ohio, the single most important recent development for the professionals keeping people in MOUD is quiet, procedural, and easy to miss on a busy Monday: State Plan Amendment OH-25-0021, which proposes to remove the September 30, 2025 sunset date on Ohio’s Medicaid MAT benefit and make it a permanent part of the State Plan ⁶.

You have probably built workflows around that sunset without meaning to. Prior authorizations timed to it. Care conferences that quietly assumed a re-approval fight in Q4. Patients who were told, however gently, that their coverage was on a clock. Making the benefit permanent takes that clock off the wall — and for someone with co-occurring depression or PTSD who has already survived one relapse cycle triggered by a coverage lapse, that is not a minor administrative detail. It is a clinical stabilizer.

The federal backdrop matters here too. Beginning October 1, 2020, states were required for a five-year period to cover FDA-approved drugs and biologicals for MAT under Medicaid, subject to limited exceptions ⁸. Ohio’s move to lock in the benefit through OH-25-0021 essentially answers the question of what happens when that federal floor expires: the Buckeye State keeps the coverage on its own footing rather than treating it as a temporary enhancement.

For your intake and utilization review teams, three practical shifts follow:

1. Treatment planning for Medicaid-covered Ohioans on methadone, buprenorphine, or extended-release naltrexone should now assume continuous coverage rather than a benefit renewal event.
2. Dual-diagnosis programming that pairs MOUD with psychiatric medication management, EMDR, or trauma-focused CBT can be built for 12- and 18-month arcs rather than the shorter horizons a sunset date imposes.
3. Patients transitioning between residential, PHP, IOP, and outpatient levels of care no longer need to be counseled through the anxiety of a looming coverage cliff — which itself is a meaningful piece of the therapeutic work.

The permanence signal is doing quiet work. Take it seriously in how you plan the next episode of care.

You already run OARRS checks. The question worth asking in 2025 is whether your workflow is actually using what OARRS now shows you — because the system has quietly grown up.

Start with the volume. In FY 2025, OARRS users requested more than 512 million patient reports, a scale that tells you two things: prescribers across Ohio are querying at every meaningful clinical decision point, and the system has become part of the connective tissue of controlled-substance care in the Buckeye State ². That is not a small compliance chore anymore. It is a workflow surface where MOUD prescribing decisions, buprenorphine continuations, and benzodiazepine co-prescribing risks all get triaged in the same view.

The bigger workflow shift is subtler. In 2024, OARRS began collecting information on non-fatal overdoses treated in Ohio emergency departments, and that indicator now surfaces inside the prescriber lookup ³. For a dual-diagnosis program, that is a concrete clinical decision-support signal — you can see, at the point of care, that the person in front of you was in a Northeast Ohio ED three weeks ago with a suspected overdose they never mentioned at intake. That changes the induction conversation. It changes the naloxone counseling. It changes the pace of the psychiatric follow-up.

The July 1, 2025 rule update tightened reporting standards and prepared the ground for a later transition to ASAP 5.0 reporting, which matters mostly for your pharmacy and dispensing partners but eventually shows up as cleaner data in your queries ¹. Fewer gaps, faster refresh, more usable overdose signal.

Two practical adjustments belong on your checklist:

1. Make the OARRS non-fatal overdose indicator a formal part of the MOUD assessment — not a passive glance, but a documented review the prescriber and the therapist both see before the treatment plan is finalized. A recent ED visit for a suspected overdose is the kind of information that should reshape the first two weeks of care, especially for a patient carrying untreated depression or trauma.
2. Treat OARRS as one instrument, not the story. Pair it with what the person tells you and what your intake screening finds. The volume of queries the state is running proves the tool works at scale; the outcome question is whether your team is letting the signal it now carries actually change what you do next.

Drive south from Columbus toward Athens, or east from Cleveland toward Jefferson County, and the map of Ohio MOUD gets thin fast. That is not an impression. It is a measurement.

A peer-reviewed geospatial modeling study of Ohio’s OTP network found that over one-third — 33.3% — of the state’s opioid use disorder treatment need was not covered by existing opioid treatment programs, with coverage dropping as county rurality increased ¹². The scope matters: this was a modeling analysis of OTP coverage relative to estimated OUD treatment need, not a headcount of every Ohioan with the diagnosis. Even with that limit, the finding is direct. The Buckeye State’s specialty methadone footprint does not reach the counties that carry a disproportionate share of the burden.

The HRSA rural MOUD policy brief names the same pattern in national terms: the rural bottleneck is a compound of prescribing barriers, dispensing barriers, and a workforce that is stretched or absent ¹¹. In practical Appalachian Ohio terms, that is a county with one primary care clinic, no OTP within an hour’s drive, a single retail pharmacy that may or may not stock buprenorphine reliably, and no in-network psychiatrist accepting new patients for the co-occurring depression, PTSD, or bipolar diagnosis your patient is also carrying.

For your dual-diagnosis planning, three implications follow:

1. A referral to “the nearest OTP” for a patient in Meigs, Vinton, or Noble County is often a referral to a two-hour round trip they will not sustain — which means office-based buprenorphine through a local FQHC or primary care partner is frequently the only realistic path to induction.
2. The rural access gap is also a mental health access gap; the same counties short on MOUD prescribers are usually short on psychiatric coverage, so telepsychiatry pairing is not a nice-to-have on the treatment plan.
3. When you are counseling a family in a Northeast Ohio catchment about a loved one who moved back home to a small town after a residential stay, the honest conversation includes whether the medication and the mental health support will actually be reachable from that ZIP code.

The 33.3% is not an abstraction. It is the reason your care coordination phone list has to be longer than your prescribing panel.

The X-waiver is gone. That was supposed to fix the office-based buprenorphine problem in Ohio. It did not, and the pre-waiver-removal data tells you why.

A descriptive study of buprenorphine access in Ohio found that of the 1,828 waivered providers in the state, fewer than half were actively prescribing, and 25% of Ohio’s counties had no buprenorphine access at all ¹³. Read that again with your care coordinator hat on: a full quarter of Buckeye State counties were prescribing zeros, and more than half of the credentialed workforce that could have been writing scripts was not writing them. The credential was never the only bottleneck. Comfort, capacity, and clinical support were.

Removing the waiver widened the pool of eligible prescribers overnight, but it did not add psychiatric consultation, care coordination time, or a hand to hold the first time a primary care physician in a small Appalachian town inducts a patient in the office. The HRSA rural brief names the same triad — prescribing, dispensing, and workforce — as the compound barrier that regulatory changes alone cannot dissolve ¹¹.

For your dual-diagnosis workflow, that changes what a warm handoff has to include. When you refer a patient back to a primary care partner for maintenance buprenorphine after a residential or PHP stay, the referral is stronger when it comes with a shared care plan, an accessible psychiatric consultation line, and a therapist who is already in the patient’s chart. Waiver removal opened the door. Whether your Ohio partners walk through it depends on what you send with the patient.

A note on scope before this one: if your role sits at a single office-based buprenorphine practice, the next few paragraphs will still be useful, but they are aimed at the program leads, care coordinators, and referral-source professionals who route Ohioans across two or more MOUD delivery models in the same week. That is the seat where the comparison actually pays off.

The four models in play across the Buckeye State are not interchangeable. Each carries a different medication scope, geographic reach, and capacity to hold a dual-diagnosis treatment plan in the same room as the prescription.

Two coordination rules follow from the table. The medication your patient needs should drive the channel — a patient stabilizing on methadone belongs in the OTP or mobile-component lane, not a primary care handoff — and the dual-diagnosis load should drive the wrapper. When co-occurring PTSD, bipolar, or major depressive symptoms are active, route toward whichever of these four models already has the therapist and the psychiatric consult inside the same chart. That is the coordination call that changes 90-day retention.

Two expansion pathways are actively rewriting where MOUD can reach in Ohio: mobile OTP components that carry the full medication scope into places a fixed clinic cannot reach, and primary care scale-up that plants buprenorphine and naltrexone prescribing inside the practices Ohioans already trust.

The DEA’s mobile-component rule was written explicitly to make it easier to provide MOUD in remote or underserved areas, letting a registered parent OTP extend its authorization to a mobile unit rather than standing up a whole new clinic ¹⁰. For the Buckeye State, that mattered because a fixed OTP in Columbus or Cleveland cannot serve a patient in Meigs or Perry County on a daily-dosing schedule — but a mobile unit tied to that same parent program can. HRSA’s rural brief frames the same expansion logic at the policy level: prescribing, dispensing, and workforce all have to move at once, or the access gap just relocates ¹¹. A mobile unit that arrives without a psychiatric consult line or a therapist connection is a dispensing solution attached to an incomplete treatment plan.

The primary care pathway is the parallel track. Ohio University researchers are scaling an NIH-funded project across roughly 40 clinics in Ohio and West Virginia to expand OUD treatment inside rural primary care rather than routing every patient to a specialty setting ¹⁴. That is the direction of travel your referral workflow should anticipate. When a patient leaves a residential stay in Massillon and heads back to a small town along the Ohio River, the sustainable next step is often the family medicine practice down the road — not a two-hour drive to the nearest OTP.

What both pathways demand from your team is the same: a warm handoff that carries the psychiatric consultation, the therapy relationship, and the OARRS-informed history along with the prescription. The infrastructure is finally moving toward your patients. Whether the dual-diagnosis piece travels with it depends on how you build the handoff.

Pull the threads together and the operational picture in Ohio gets clearer. Coverage is stabilizing, monitoring is sharper, and the delivery-model map has more lanes than it did five years ago. What separates programs that hold their patients from programs that lose them is not access to any single one of these — it is whether the referral and coordination practice was rebuilt to use all of them together.

Three shifts belong on your team’s dashboard this quarter:

1. Rewrite treatment plans for continuous Medicaid MAT coverage rather than a sunset event, and lengthen the dual-diagnosis arc accordingly ⁶.
2. Make the OARRS non-fatal overdose indicator a documented step in every MOUD assessment, shared between the prescriber and the therapist ³.
3. Match the delivery model to the county, not the intake preference — an Appalachian patient may need FQHC-based buprenorphine with telepsychiatry, while a Massillon or Cleveland patient may fit an OTP with on-site behavioral health.

This work is hard, and you already know that. If your program is looking for a dual-diagnosis partner in the Northeast Ohio corridor who builds MOUD and mental health treatment into the same plan, Arrow Passage Recovery is one place to start that conversation.